RedHill Biopharma Ltd.
RDHL
$2.07
-$0.065-3.04%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 382.03% | 382.03% | -28.40% | -95.57% | -96.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 382.03% | 382.03% | -28.40% | -95.57% | -96.77% |
| Cost of Revenue | 71.76% | 71.76% | -12.90% | -93.95% | -94.49% |
| Gross Profit | 3,818.09% | 3,818.09% | -41.01% | -98.88% | -99.42% |
| SG&A Expenses | -45.37% | -45.37% | -44.44% | -53.87% | -55.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.59% | -29.59% | -11.19% | -71.04% | -73.29% |
| Operating Income | 68.39% | 68.39% | 4.17% | 39.49% | 15.31% |
| Income Before Tax | 80.88% | 80.88% | -302.89% | -263.18% | 62.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 80.88% | 80.88% | -302.89% | -263.18% | 62.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 80.88% | 80.88% | -302.89% | -263.18% | 62.07% |
| EBIT | 68.39% | 68.39% | 4.17% | 39.49% | 15.31% |
| EBITDA | 67.84% | 67.77% | -11.05% | 40.45% | -12.38% |
| EPS Basic | 94.20% | 94.20% | -122.05% | 30.74% | 93.80% |
| Normalized Basic EPS | 96.66% | 96.66% | 99.15% | 34.53% | 94.14% |
| EPS Diluted | 94.20% | 94.20% | -122.05% | 30.74% | 93.80% |
| Normalized Diluted EPS | 96.66% | 96.66% | 99.15% | 34.53% | 94.14% |
| Average Basic Shares Outstanding | 229.96% | 229.96% | 820.19% | 424.16% | 512.07% |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |